↑ 疾患リストへ ← 戻る

 298. 遺伝性膵炎 [臨床試験数:79,薬物数:116(DrugBank:44),標的遺伝子数:46,標的パスウェイ数:121] 

Searched query = "Hereditary pancreatitis", "Chronic pancreatitis"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"    Synonyms (DrugBank) were also searched for.
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03568630July 26, 20183 December 2018Blood Markers of Early Pancreas CancerA Longitudinal Cohort Study to Identify Clinical and Blood Markers of Early Pancreas CancerDiabetes Mellitus, Type 2;PreDiabetes;Pancreas Cyst;Chronic Pancreatitis;Genetic Predisposition to Disease;Inherited DiseaseDiagnostic Test: Other exploratory blood biomarkers;Diagnostic Test: Hemoglobin A1c;Diagnostic Test: Mixed Meal Tolerance TestUniversity of NebraskaNational Cancer Institute (NCI)Recruiting19 YearsN/AAll1250Phase 2United States
2JPRN-UMIN0000307352018/01/1522 July 2019Diagnostic accuracy of contrast enhanced endoscopic ultrasonography in pancreatbiliary diseaseDiagnostic accuracy of contrast enhanced endoscopic ultrasonography in pancreatbiliary disease - A clinical trial of contrast enhanced endoscopic ultrasonography in the pancreatobiliary diseasePancreas tumor, Chronic pancreatitis, Autoimmune pancreatitis, Gallblader polyp, Biliary tract tumorContrast enhanced endoscopic ultrasonography using perflubutane
MRI
enhanced CT
endoscopic ultrasonography without perflubutane
Department of Endoscopy The Jikei University School of MedicineNot Recruiting20years-old100years-oldMale and Female786Not selectedJapan
3NCT03283566October 3, 201730 September 2019Hydroxychloroquine and Metabolic Outcomes in Patients Undergoing TPAITHydroxychloroquine and Metabolic Outcomes in Patients Undergoing Total Pancreatectomy and Autologous Islet Transplantation: A Clinical, Molecular, and Genomic StudyChronic Pancreatitis;Insulin Dependent DiabetesDrug: Hydroxychloroquine;Drug: PlaceboThe Cleveland ClinicAllegheny Singer Research Institute (also known as Allegheny Health Network Research Institute);Stanford UniversityRecruiting18 Years65 YearsAll10Phase 2United States
4NCT03244683August 28, 201714 October 2019A Study of the Efficacy of ONS to Reduce Postoperative Complications Associated With Pancreatic SurgeryA Study of the Efficacy of Oral Nutritional Supplementation to Reduce Postoperative Complications Associated With Pancreatic SurgeryPancreatic Cancer;Chronic PancreatitisDietary Supplement: Ensure Surgical;Other: Nutrition counseling;Other: Low-intensity exercise therapyOhio State UniversityAbbott NutritionNot recruiting40 Years89 YearsAll150N/AUnited States
5EUCTR2017-000732-34-DK21/06/201724 July 2017Drug Release and Absorption from Controlled Release Formulations in Patients with Gastrointestinal Dysfunctions.Oral Controlled Release Formulations to Patients with Gastrointestinal Dysfunction – Is the Release of Drug and the Absorption Impaired? - ABOXYHealthy (pain) and patients (pain).
MedDRA version: 20.0 Level: LLT Classification code 10009093 Term: Chronic pancreatitis System Organ Class: 100000016350
MedDRA version: 20.0 Level: LLT Classification code 10012594 Term: Diabetes System Organ Class: 100000019275
MedDRA version: 20.0 Level: LLT Classification code 10048516 Term: Gastrointestinal disorder (NOS) System Organ Class: 100000016398
MedDRA version: 20.0 Level: LLT Classification code 10050554 Term: Gastric bypass NOS System Organ Class: 100000021740 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Oxynorm
Product Name: Oxynorm
Pharmaceutical Form: Oral solution
INN or Proposed INN: Oxycodone
CAS Number: 124-90-3
Other descriptive name: OXYCODONE
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 1-
Trade Name: Oxycodonhydrochlorid ”Lannacher”, depot tablets
Product Name: Oxycodonhydrochlorid ”Lannacher”, depot tablets
Pharmaceutical Form: Modified-release tablet
INN or Proposed INN: Oxycodone
CAS Number: 124-90-3
Other descriptive name: OXYCODONE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 20-
Trade Name: Oxycodone Depot ”Sandoz”, depot tablets
Product Name: Oxycodone Depot ”Sandoz”, depot tablets
Pharmaceutical Form: Modified-release tablet
INN or Proposed INN: Oxycodone
CAS Number: 124-90-3
Other descriptive name: OXYCODONE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 20-
Mech-Sense, Dept. Gastroenterology & Hepatology, Aalborg University HospitalAuthorisedFemale: yes
Male: yes
Phase 1;Phase 4Denmark
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT03481803January 27, 20179 October 2018A Phase IIa Study With Escalating Dose of MS1819-SDA Multicentre Open-label Phase IIa Study With Escalating Dose of MS1819- SD, to Investigate the Efficacy and Safety of a Yarrowia Lipolytica Lipase Preparation for the Compensation of Exocrine Pancreatic Insufficiency Caused by Chronic Pancreatitis and/or Distal PancreatectomyChronic Pancreatitis;Distal PancreatectomyDrug: MS1819-SDAzurRx SASNot recruiting18 YearsN/AAll11Phase 2Australia;France;New Zealand
7NCT02713997December 201611 November 2019Anti-inflammatory Therapy to Improve Outcomes After TPIATAnti-inflammatory Therapy to Improve Outcomes in Patients With Chronic Pancreatitis Undergoing Total Pancreatectomy Islet AutotransplantationPancreatitis, Chronic; Diabetes; TransplantDrug: etanercept;Drug: Alpha 1-AntitrypsinUniversity of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Recruiting18 Years65 YearsAll45Phase 4United States
8NCT02971475November 201611 June 2018ESWL Versus ESWL and Endoscopic TreatmentExtracorporeal Shock Wave Lithotripsy Versus Extracorporeal Shock Wave Lithotripsy Combined With Endoscopic Treatment for Painful Calcified Chronic PancreatitisPancreatitisProcedure: extracorporeal shock wave lithotripsy;Procedure: endoscopic drainage of the main pancreatic duct;Drug: AnalgesicsChanghai HospitalRecruiting18 YearsN/AAll62N/AChina
9NCT02947087October 201614 January 2019Alpha-1 Antitrypsin (AAT) Enhances Islet Autograft Survival in Patients With Chronic PancreatitisAlpha-1 Antitrypsin (AAT) Enhances Islet Autograft SurvivalChronic PancreatitisDrug: Placebo;Drug: Prolastin-CMedical University of South CarolinaRecruiting18 YearsN/AAll48Phase 1/Phase 2United States
10NCT02743364September 19, 201628 October 2019Simvastatin in Reducing Pancreatitis in Patients With Recurrent, Acute or Chronic PancreatitisStatin Therapy to Reduce the Risk of Recurrent PancreatitisAcute PancreatitisOther: Laboratory Biomarker Analysis;Other: Placebo;Other: Quality-of-Life Assessment;Other: Questionnaire Administration;Drug: SimvastatinNational Cancer Institute (NCI)Not recruiting18 YearsN/AAll30Phase 2United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT02965898September 201622 October 2019The Effect of Vitamin D Substitution on the Development of Chronic PancreatitisThe Effect of Vitamin D Substitution on Pancreatic Parenchyma and Development of Fibrosis After First Acute Alcoholic Pancreatitis: A Randomized Prospective TrialChronic PancreatitisDietary Supplement: Vitamin D 100ug;Dietary Supplement: Vitamin D 10ugTampere University HospitalOrion Corporation, Orion PharmaRecruiting18 Years101 YearsAll260N/AFinland
12NCT02869893August 10, 201630 September 2019MRCP: A Reliable, Non Invasive Method for Staging Chronic Pancreatitis in PediatricsMagnetic Resonance Cholangiopancreatography (MRCP): A Reliable, Non Invasive Method for Staging Chronic Pancreatitis From Minimal Change Disease to the Advanced Stages in PediatricsHealthy VolunteersDrug: SecretinChildren's Hospital Medical Center, CincinnatiChiRhoClin, Inc.;The National Pancreas FoundationNot recruiting6 Years15 YearsAll57N/AUnited States
13NCT02849704July 201612 February 2018Fat Malabsorption in Chronic PancreatitisDiagnosing Pancreatic-Based Malabsorption in Patients With Chronic PancreatitisChronic PancreatitisDrug: Creon36™Children's Hospital of PhiladelphiaAbbVie;National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);Phoenix Indian Medical CenterRecruiting30 Years70 YearsAll48Phase 2United States
14NCT02706236April 20165 March 2018Trial of Pancreatic Enzyme Supplements (Pancrelipase) for Treating Pain in Patients With Chronic PancreatitisA Single-Center Prospective Randomized Placebo Controlled Trial of Pancreatic Enzyme Supplements (Pancrelipase) for Treating Pain in Patients With Chronic PancreatitisPancreatitisDrug: Pancrelipase;Drug: placeboDartmouth-Hitchcock Medical CenterNot recruiting18 YearsN/AAll0Phase 2United States
15EUCTR2015-002570-20-ES25/02/201625 April 2016Optimizing treatment of maldigestion in patients with chronic pancreatitisOpen label, randomized, crossover clinical trial to evaluate the efficacy of increasing doses of pancreatic enzymes against inhibition of acid gastric secretion in patients with exocrine pancreatic insufficiency secondary to chronic pancreatitisPatients diagnosed of chronic pancreatitis with pancreatic exocrine insufficiency under pancreatic enzyme replacement therapy;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]Trade Name: Kreon 25000
Product Name: Creon 25000
Product Code: PL 00512/0150
Pharmaceutical Form: Capsule
Department of gastroenterology. University Hospital of SantiagoAuthorisedFemale: yes
Male: yes
Spain
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16NCT02693093December 20154 November 2019A Dose Ranging Study Evaluating Efficacy and Safety of NI-03A Phase 1, Single Dose PK and Safety Study With NI-03 Followed by a Phase 2, Randomized, Double-Blind, Parallel-Group Dose-Ranging Study to Evaluate the Safety and Efficacy of NI-03 When Compared to Placebo in Subjects With Chronic PancreatitisChronic PancreatitisDrug: NI-03;Drug: PlaceboKangen Pharmaceuticals, IncRecruiting18 Years85 YearsAll128Phase 1/Phase 2United States
17NCT02538146August 201516 December 2017Effect of Acetyl-L-carnitine on Chronic PancreatitisAcetyl-L-carnitine as Pain Therapy in Chronic PancreatitisChronic PancreatitisDietary Supplement: acetyl-L-carnitine 1000mg 2X per day for 3 monthsKarin HighUniversity of KentuckyNot recruiting20 Years90 YearsAll3Early Phase 1United States
18NCT02577640July 201516 December 2017Dietary Soy Isoflavones In Chronic PancreatitisDietary Soy Isoflavones In Chronic PancreatitisChronic PancreatitisDietary Supplement: Soy breadOhio State UniversityNot recruiting18 YearsN/AAll11N/AUnited States
19NCT02487225May 20155 March 2018Pentoxifylline Treatment in Acute Pancreatitis (AP)Pentoxifylline Treatment in Acute Pancreatitis: A Double-Blind Placebo - Controlled Randomized TrialAcute Pancreatitis (AP);Gallstone Pancreatitis;Alcoholic Pancreatitis;Post-ERCP/Post-procedural Pancreatitis;Trauma Acute Pancreatitis;Hypertriglyceridemia Acute Pancreatitis;Idiopathic (Unknown) Acute Pancreatitis;Medication Induced Acute Pancreatitis;Cancer Acute Pancreatitis;Miscellaneous (i.e. Acute on Chronic Pancreatitis)Drug: Pentoxifylline;Drug: PlaceboMayo ClinicNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Not recruiting18 Years100 YearsAll83Phase 3United States
20NCT02567240January 201514 January 2019Carbon Monoxide-Saturated Medium for Islet IsolationA Novel Approach to Harvest Islets for Autologous Islet TransplantationChronic PancreatitisOther: Carbon monoxide-bubbled mediumsMedical University of South CarolinaNot recruiting18 Years69 YearsAll16Phase 1/Phase 2United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
21NCT02384018December 201414 January 2019Mesenchymal Stem Cell and Islet Co-transplantationA Phase I Study Evaluating Safety and Tolerability of Autologous Bone Marrow-derived Mesenchymal Stromal Cells in Chronic Pancreatitis Patients Who Undergo Total Pancreatectomy and Islet Autotransplantation.Chronic Pancreatitis;DiabetesBiological: autologous mesenchymal stromal cellMedical University of South CarolinaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Not recruiting18 Years69 YearsAll24Phase 1United States
22NCT02399800December 201426 February 2018Celiac Plexus Block for Chronic Pancreatitis RCTProspective Randomized Trial of EUS Guided Celiac Plexus Block for Chronic PancreatitisPancreatitis, Chronic;PancreatitisProcedure: Celiac Block with triamcinolone and bupivicaine;Procedure: No Celiac Block;Drug: Intra Plexus Triamcinolone and Bupivicaine InjectionUniversity of Southern CaliforniaNot recruiting18 YearsN/AAll1N/AUnited States
23NCT01967888February 201428 October 2019Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantationA Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantationPancreatectomy for Chronic PancreatitisDrug: Reparixin;Drug: PlaceboDompé Farmaceutici S.p.ANot recruiting18 YearsN/AAll104Phase 2/Phase 3United States;Canada
24EUCTR2013-003357-17-DK01/11/201314 November 2016The Ketamine - a novel approach to treating painful chronic pancreatitis.RESET Trial A randomized, double-blinded, single-centre, parallel-group, placebo-controlled, prospective trial of S-ketamine for pain treatment in chronic pancreatitis (RESET trial) - RESET TrialChronic Pancreatitis
MedDRA version: 17.1 Level: LLT Classification code 10009093 Term: Chronic pancreatitis System Organ Class: 100000004856
MedDRA version: 17.1 Level: HLT Classification code 10033646 Term: Acute and chronic pancreatitis System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Trade Name: S-Ketamin
Product Name: S-ketamin
Pharmaceutical Form: Concentrate for solution for infusion
Trade Name: Midazolam
Product Name: Midazolam
Pharmaceutical Form: Solution for injection/infusion
Pharmaceutical form of the placebo: Solution for injection/infusion
Route of administration of the placebo: Intravenous use
Prof. Asbjørn Mohr DrewesNot RecruitingFemale: yes
Male: yes
60Phase 4Denmark
25JPRN-UMIN0000131822013/10/162 April 2019Efficacy of the pancrelipase for early chronic pancreatitisearly chronic pancreatitisPancrelipase
no treatment
Fukushima Medical University Aizu Medical CenterRecruitingNot applicableNot applicableMale and Female60Not selectedJapan
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
26EUCTR2012-004170-26-IT04/12/20122 June 2014Randomized double blinde placebo controlled trial to evaluate the efficacy of N-acetylcystein in patients with chronic pancreatitis and primary sclerosing cholangitis.Randomized double blinde placebo controlled trial to evaluate the efficacy of N-acetylcystein in patients with chronic pancreatitis and primary sclerosing cholangitis.Chronic pancreatitis and primary sclerosing cholangitis
MedDRA version: 15.0 Level: PT Classification code 10033649 Term: Pancreatitis chronic System Organ Class: 10017947 - Gastrointestinal disorders
MedDRA version: 15.0 Level: PT Classification code 10008609 Term: Cholangitis sclerosing System Organ Class: 10019805 - Hepatobiliary disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Trade Name: FLUIMUCIL*20CPR EFF 600MG
Pharmaceutical Form: Effervescent tablet
INN or Proposed INN: ACETYLCYSTEINE
CAS Number: 616-91-1
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 600-
Pharmaceutical form of the placebo: Effervescent tablet
Route of administration of the placebo: Oral use
POLICLINICO UNIVERSITARIO AGOSTINO GEMELLINot RecruitingFemale: yes
Male: yes
200Italy
27NCT01551511October 201219 February 2015?9-THC (Namisol®) in Chronic Pancreatitis Patients Suffering From Persistent Abdominal Pain?9-THC (Namisol®) in Chronic Pancreatitis Patients Suffering From Persistent Abdominal Pain: a Randomized, Double-blinded, Placebo-controlled, Parallel DesignPancreatitis, Chronic;Abdominal Pain;Chronic PainDrug: Tetrahydrocannabinol;Drug: PlaceboRadboud UniversityEuropean UnionNot recruiting18 YearsN/ABoth29Phase 2Netherlands
28EUCTR2012-000730-19-NL23/08/201228 August 2012?9-THC (Namisol®) in Chronic Pancreatitis Patients Suffering From Persistent Abdominal PainThe analgesic efficacy of ?9-THC (Namisol®) in Chronic Pancreatitis Patients Suffering From Persistent Abdominal Pain: a Randomized, Double-blinded, Placebo-controlled, Parallel Design - Delta-Pain IIChronic pancreatitis with persistant abdominal pain
MedDRA version: 14.1 Level: PT Classification code 10033649 Term: Pancreatitis chronic System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Body processes [G] - Digestive System and Oral Physiological Phenomena [G10]
Product Name: Namisol
Product Code: A04AD10
Pharmaceutical Form: Tablet
INN or Proposed INN: DRONABINOL
CAS Number: 03/08/1972
Other descriptive name: Tetrahydro-6,6,9-tri methyl-3-penthyl-6 H-dibenzo[ b,d ]pyran-1-ol
Concentration unit: mg milligram(s)
Concentration type: range
Concentration number: 0.75-5.0
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Radboud University Nijmegen Medical CentreAuthorisedFemale: yes
Male: yes
Netherlands
29JPRN-UMIN0000095472012/08/012 April 2019Prospectivestudy on the treatment effect of pancrelipase on chronic pancreatitis patient's alubumin concentrationChronic pancreatitis600mg of Pancrelipase (granules or capsels) to be taken three times a day (1800mg /day) after meals for 4 weeks.Department of Internal Medicine Second Teaching Hospital Fujita Health University School of MedicineRecruiting20years-oldNot applicableMale and Female83Not applicableJapan
30NCT02458118June 201214 March 2016Pancreatic Perfusion Using Secretin and MRIStudy to Assess Pancreatic Blood Flow at Rest and During Stimulation Using Magnetic Resonance Imaging (fMRI) in Patients With Chronic PancreatitisChronic PancreatitisDrug: SecretinUniversity of NottinghamRecruiting18 Years80 YearsBoth15Phase 1/Phase 2United Kingdom
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
31NCT01528540April 201221 September 2015Evaluation of Efficacy of Combination of Pregabalin and Antioxidant in Reducing Pain in Chronic Pancreatitis: a Randomized Control TrialEvaluation of Efficacy of Combination of Pregabalin and Antioxidant in Reducing Pain in Chronic Pancreatitis: a RCTChronic PancreatitisDrug: Placebo;Drug: Antioxidant plus PregabalinAsian Institute of Gastroenterology, IndiaNot recruiting18 Years65 YearsBoth87N/AIndia
32NCT01318369October 201119 February 2015Efficacy Study of ?9-THC to Treat Chronic Abdominal PainThe Safety, Tolerability, and Analgesic Efficacy of ?9-THC (Namisol®) in Chronic Pancreatitis Patients Suffering From Persistent Abdominal PainCannabinoid;Tetrahydrocannabinol;Chronic Pancreatitis;Abdominal PainDrug: Namisol;Drug: DiazepamRadboud UniversityNot recruiting18 YearsN/ABoth24Phase 2Netherlands
33NCT01430234October 201123 March 2015Enzyme Suppletion in Exocrine Pancreatic DysfunctionEnzyme Substitution in Exocrine Pancreatic Insufficiency; Self Administration Against a Fixed Dose RegimenChronic Pancreatitis;Exocrine Pancreatic InsufficiencyDrug: Panzytrat 25.000 FIP-E units of LipaseFoundation for Liver ResearchAxcan PharmaNot recruiting18 Years90 YearsBoth10Phase 4Netherlands
34EUCTR2010-020303-69-NL19/09/201119 March 2012Enzyme substitution in exocrine pancreatic insufficiency; Self administration against a fixed dose regimen. - SAPESEnzyme substitution in exocrine pancreatic insufficiency; Self administration against a fixed dose regimen. - SAPESExocrine pancreatic insufficiency in patients with chronic pancreatitis
MedDRA version: 12.1 Level: LLT Classification code 10041969 Term: Steatorrhoea
Trade Name: Panzytrat
Product Name: Panzytrat
Product Code: RVG 13760
Pharmaceutical Form: Capsule, soft
INN or Proposed INN: pancreatic enzymes
CAS Number: 9001621
Other descriptive name: LIPASE
Concentration unit: IU international unit(s)
Concentration type: equal
Concentration number: 25000-
Erasmus MCAuthorisedFemale: yes
Male: yes
20Netherlands
35NCT01318590March 201116 December 2017Prospective Study on Endoscopic Ultrasound (EUS) Celiac Bloc Efficacy in Chronic PancreatitisProspective Study on Endoscopic Ultrasound (EUS) Celiac Bloc Efficacy in Chronic PancreatitisPancreatitis, ChronicDrug: Bupivacaine & Triamcinolone Acetonide;Other: No intervention except EUS procedureCentre hospitalier de l'Université de Montréal (CHUM)Centre de Recherche du Centre Hospitalier de l'Université de Montréal;Erasme University HospitalRecruiting18 YearsN/AAll100Phase 3Belgium;Canada
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
36NCT01265875December 201019 October 2017Secretin Infusion for Pain Due to Chronic PancreatitisSecretin Infusion for Pain Due to Chronic PancreatitisChronic PancreatitisDrug: Human SecretinChiRhoClin, Inc.Dartmouth-Hitchcock Medical CenterNot recruiting18 Years70 YearsAll12Phase 1/Phase 2United States
37NCT01146561October 201019 February 2015Safety And Efficacy Of Tanezumab In Patients With Chronic PancreatitisA Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Of The Analgesic Efficacy And Safety Of Tanezumab In Patients With Chronic PancreatitisChronic PancreatitisBiological: Tanezumab;Other: PlaceboPfizerNot recruiting18 YearsN/ABoth2Phase 2United States
38NCT01452217September 201019 February 2015Non-invasive MRI to Quantify the Effect of Secretin on Pancreatic Blood Flow and Perfusion in Healthy VolunteersThe Use of Non-invasive MRI to Quantify the Effect of Secretin on Pancreatic Blood Flow and Perfusion in Healthy VolunteersChronic PancreatitisDrug: SecretinUniversity of NottinghamNot recruiting18 Years75 YearsMale12Phase 1United Kingdom
39NCT01159119August 201019 February 2015A Study of EUR-1066 in Subjects With Chronic Pancreatitis, Exocrine Pancreatic Insufficiency and Chronic Abdominal PainSingle Center Randomized Single Blind Crossover Group Active Control Study to Evaluate Safety and Efficacy of EUR-1066 a Pancreatic Enzyme Product in Patients With Chronic Pancreatitis Exocrine Pancratic Insufficiency,Chronic Abdominal PainChronic PancreatitisDrug: EUR-1066-A;Drug: Zenpep;Drug: EUR-1066-BEurand PharmaceuticalsUniversity of FloridaNot recruiting18 YearsN/ABoth15Phase 1United States
40NCT01236053June 201016 December 2017Cancer in Patients With Gabapentin (GPRD)Risk of Cancer in Patients Exposed to Gabapentin in the GPRDPain, Neuropathic;Epilepsy;Renal Pelvis Cancer;Pancreatic Cancer;Breast Cancer;Nervous System Cancer;Chronic Pancreatitis;Stomach Cancer;Renal Cell Carcinoma;Diabetes;Bladder Cancer;Bone and Joint Cancer;Penis Cancer;Anal Cancer;Cancer;Renal CancerDrug: Gabapentin prescriptionsGlaxoSmithKlineNot recruitingN/AN/AAll2323608N/A
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
41EUCTR2010-018900-10-FR11/05/201019 March 2012Safety and preliminary clinical activity of Yarrowia lipolytica lipase (MS1819) in patients with malabsorption syndrome due to exocrine pancreatic insufficiency resulting from chronic pancreatitisSafety and preliminary clinical activity of Yarrowia lipolytica lipase (MS1819) in patients with malabsorption syndrome due to exocrine pancreatic insufficiency resulting from chronic pancreatitisExocrine pancreatic insufficiency resulting from chronic pancreatitis
MedDRA version: 12.1 Level: LLT Classification code 10033628 Term: Pancreatic insufficiency
Product Name: MS1819
Product Code: MS1819
Pharmaceutical Form: Powder for oral solution
INN or Proposed INN: Yarrowia lipolytica lipase
Current Sponsor code: MS1819
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10-
Pharmaceutical form of the placebo: Powder for oral solution
Route of administration of the placebo: Oral use
Laboratoires Mayoly SpindlerAuthorisedFemale: yes
Male: yes
12France
42EUCTR2005-000562-38-DE20/04/201010 February 2014RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED PHASE IV TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A GASTRO-RESISTANT FILM-COATED PANCREATIN TABLET FOR LIPID DIGESTION AND ABSORPTION IN PATIENTS WITH PANCREATIC EXOCRINE INSUFFICIENCY DUE TO CHRONIC PANCREATITIS BY MEANS OF 13C-MIXED TRIGLYCERIDE BREATH TEST - CPI 002RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED PHASE IV TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A GASTRO-RESISTANT FILM-COATED PANCREATIN TABLET FOR LIPID DIGESTION AND ABSORPTION IN PATIENTS WITH PANCREATIC EXOCRINE INSUFFICIENCY DUE TO CHRONIC PANCREATITIS BY MEANS OF 13C-MIXED TRIGLYCERIDE BREATH TEST - CPI 002The purpose of this trial is to evaluate the clinical efficacy and safety of a gastro-resistant film-coated tablet in comparison to placebo in the treatment of pancreatic exocrine insufficiency due to chronic pancreatitis
MedDRA version: 7.0 Level: LLT Classification code 10033628
Trade Name: Mezym F
Product Name: Mezym F
Product Code: Pancreatin
Pharmaceutical Form: Gastro-resistant tablet
INN or Proposed INN: Pancreatin
Concentration unit: IU international unit(s)
Concentration type: not less then
Concentration number: 10000 IU lipase-
Pharmaceutical form of the placebo: Gastro-resistant tablet
Route of administration of the placebo: Oral use
Berlin-Chemie AGNot RecruitingFemale: yes
Male: yes
20Phase 4Germany
43EUCTR2009-016082-29-BE10/03/201014 October 2013Role of Lanreotide in the Management of Paraduodenal Pancreatitis - LPPRole of Lanreotide in the Management of Paraduodenal Pancreatitis - LPPParaduodenal pancreatitis
MedDRA version: 12.1 Level: LLT Classification code 10009093 Term: Chronic pancreatitis
Trade Name: Somatuline Autogel 90 mg
Pharmaceutical Form: Solution for injection
CAS Number: 127984741
Other descriptive name: LANREOTIDE ACETATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 90-
Pharmaceutical form of the placebo: Solution for injection
Route of administration of the placebo: Subcutaneous use
Erasme hospitalAuthorisedFemale: yes
Male: yes
60Belgium
44NCT01138124March 201016 December 2017Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD)Risk of Pancreatic Cancer and Renal Cancer in Patients Exposed to Gabapentin in the United Kingdom General Practice Research DatabaseRenal Pelvis Cancer;Restless Legs Syndrome;Epilepsy;Neuropathic Pain;Chronic Pancreatitis;Hypertension;Pancreatic Cancer;Diabetes;Renal Cancer;Renal Cell CarcinomaDrug: Gabapentin prescriptionsGlaxoSmithKlineNot recruitingN/AN/AAll54202N/A
45JPRN-UMIN0000030202010/01/012 April 2019Establishment of pancreatic exocrine function assaay usin real time 13C breath test.Chronic pancreatitis, state after pancreatectomyExpiratory 13CO2 measurement after oral intake of 13C incorporated fatty acids and amino acids in healthy volunteers.
Expiratory 13CO2 measurement after oral intake of 13C incorporated fatty acids and amino acids in patients after total pancreatectomy.
Expiratory 13CO2 measurement after oral intake of 13C incorporated fatty acids and amino acids in patients after pancreatico duodenectomy.
Expiratory 13CO2 measurement after oral intake of 13C incorporated fatty acids and amino acids in patients with chronic pancreatits.
Tohoku University HospitalRecruiting20years-old80years-oldMale and Female8Not applicableJapan
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
46NCT01001923December 200919 February 2015Single Injection of REGN475/SAR164877 in the Treatment of Chronic Pancreatitis PainRandomized, Double-blind, Placebo-controlled Study of the Effect of a Single Injection of SAR164877 (REGN475) on Reduction of Pain From Chronic PancreatitisAbdominal Pain UpperDrug: REGN475/SAR164877;Drug: Placebo (for REGN475/SAR164877)Regeneron PharmaceuticalsNot recruiting18 Years80 YearsBoth15Phase 2United States
47NCT01141998December 200919 February 2015Vitamin D Substitution for Patients With Chronic Pancreatitis and MalabsorptionVitamin D Substitution for Patients With Chronic Pancreatitis and MalabsorptionChronic Pancreatitis;Malabsorption SyndromesDrug: Cholecalciferol;Radiation: UV-filtered light.;Radiation: UVB;Drug: Calcium, DietaryHvidovre University HospitalNot recruiting18 YearsN/ABoth27N/ADenmark
48EUCTR2009-010266-28-NL21/07/200919 March 2012Een gerandomiseerde dubbelblinde, placebogecontroleerde, klinische parallelle groep studie van pregabaline in patiënten met chronische pancreatitis - Effect van pregabaline therapie bij patiënten met chronische pancreatitisEen gerandomiseerde dubbelblinde, placebogecontroleerde, klinische parallelle groep studie van pregabaline in patiënten met chronische pancreatitis - Effect van pregabaline therapie bij patiënten met chronische pancreatitischronische pancreatitis
MedDRA version: 9.1 Level: LLT Classification code 10009093 Term: Chronic pancreatitis
Trade Name: Lyrica®
Pharmaceutical Form: Capsule, hard
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Afdeling heelkunde, Universitair Medisch Centrum Sint RadboudAuthorisedFemale: yes
Male: yes
30Netherlands
49NCT01142128February 200919 October 2017Viokase 16, Viokase16 Plus Nexium and Nexium AloneA Randomized, Single Site, Double Blind, Fixed Dose, Cross Over Study of Viokase 16, Viokase16 Plus Nexium and Nexium Alone in the Reduction of Abdominal Pain in Patients With Chronic PancreatitisChronic PancreatitisDrug: Nexium (esomeprazole magnesium);Drug: Placebo to Nexium;Drug: Viokase 16 (pancrelipase) + Nexium;Drug: Viokase 16 + placebo to NexiumUniversity of FloridaAstraZenecaNot recruiting18 Years75 YearsAll12Phase 1United States
50NCT01259544January 200919 February 2015BreathID® Test: A Non-invasive Modality to Detect Pancreatic Exocrine InsufficiencyChronic Pancreatitis;Healthy VolunteersDrug: benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala)Exalenz Bioscience LTD.Virginia Commonwealth University;Asian Institute of Gastroenterology, Hyderabad, IndiaNot recruiting18 YearsN/ABoth33Phase 2India
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
51NCT00782795November 200816 December 2017Chronic Pancreatitis. Effect of Pioglitazone on Endocrine Function, Exocrine Function & Structure, Pain & Life QualityPhase II Study of Chronic Pancreatitis and the Effect of Pioglitazone on Endocrine Function, Exocrine Function & Structure, Pain & Life QualityChronic Pancreatitis;Insulin Resistance;Normal or Mildly Abnormal Stool Fat LevelsDrug: Pioglitazone;Drug: PlaceboUniversity of MichiganNational Institute on Alcohol Abuse and Alcoholism (NIAAA);Takeda Pharmaceuticals North America, Inc.Not recruiting18 Years75 YearsAll64Phase 2United States
52NCT00755573October 200819 February 2015Pain and Chronic Pancreatitis - Clinical End Experimental StudiesA Randomized, Double-Blind, Placebo-Controlled, Parallel Group Clinical and Experimental Pilot Study of Pregabalin in Patients With Chronic PancreatitisChronic PancreatitisDrug: Pregabalin;Drug: placeboAalborg UniversitetshospitalRadboud UniversityNot recruiting18 Years75 YearsBoth64Phase 2/Phase 3Denmark;Netherlands
53NCT00744250August 200819 February 2015Intraduodenal Aspiration Study to Assess the Bioavailability of Oral Pancrecarb® Compared to Placebo ControlIntraduodenal Aspiration Study to Assess the Bioavailability of Oral Pancrecarb® Compared to Placebo Control in Patients With Pancreatic InsufficiencyExocrine Pancreatic Insufficiency;Chronic Pancreatitis;Cystic FibrosisDrug: PancrelipaseDigestive Care, Inc.University of North Carolina, Chapel HillNot recruiting18 YearsN/ABoth3Phase 4United States
54EUCTR2008-002671-27-DK14/07/200817 October 2016A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP CLINICAL AND EXPERIMENTAL PILOTSTUDY OF PREGABALIN IN PATIENTS WITH CHRONIC PANCREATITISA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP CLINICAL AND EXPERIMENTAL PILOTSTUDY OF PREGABALIN IN PATIENTS WITH CHRONIC PANCREATITISChronic pancreatitis
MedDRA version: 9.1 Level: LLT Classification code 10033649 Term: Pancreatitis chronic
Trade Name: Lyrica
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: pregabalin
CAS Number: 148553508
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 150-
INN or Proposed INN: Pregabalin
CAS Number: 148553508
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 150-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Department of Medical GastroenterologyNot RecruitingFemale: yes
Male: yes
45Phase 3Denmark
55NCT00401076July 200819 February 2015A Open-label Study to Assess the Safety of Oral Long-term Use of SA-001 in Pancreatic Exocrine InsufficiencyA One-year Open-label Study to Assess the Safety of Oral Long-term Use of SA-001 in Patients With Pancreatic Exocrine Insufficiency Caused by Chronic Pancreatitis or by PancreatectomyPancreatic Exocrine Insufficiency, Chronic Pancreatitis, PancreatectomyDrug: SA-001AbbottNot recruiting20 YearsN/ABoth80Phase 3Japan
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
56NCT00705978June 200819 February 2015Creon 40,000 for Treatment of PEI (Pancreatic Exocrine Insufficiency) Due to Chronic PancreatitisA One Week Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Center Study With Creon 40,000 MMS in Subjects With Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis, Followed by an Open-Label Long-Term ExtensionPancreatic InsufficiencyDrug: Pancreatin;Drug: PlaceboAbbott ProductsQuintiles, DatamapNot recruiting18 YearsN/ABoth62Phase 3India
57EUCTR2008-000061-37-IT02/04/200819 March 2012A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Safety and Efficacy of two doses of Zentase? (EUR-1008) in Chronic Pancreatitis (CP) patients with Exocrine Pancreatic Insufficiency (EPI) - PR-002A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Safety and Efficacy of two doses of Zentase? (EUR-1008) in Chronic Pancreatitis (CP) patients with Exocrine Pancreatic Insufficiency (EPI) - PR-002Chronic Pancreatitis (CP) with Exocrine Pancreatic Insufficiency (EPI)
MedDRA version: 9.1 Level: SOC Classification code 10017947 Term: Gastrointestinal disorders
Product Name: ZENTASE
Pharmaceutical Form: Gastro-resistant capsule, hard
INN or Proposed INN: Multienzymes (lipase, protease etc.)
Concentration unit: U unit(s)
Concentration type: equal
Concentration number: 20-
Pharmaceutical form of the placebo: Gastro-resistant capsule, hard
Route of administration of the placebo: Oral use
EURAND SPANot RecruitingFemale: yes
Male: yes
72Italy
58NCT00559052March 200819 February 2015An Open-Label Study to Evaluate the Intraduodenal Delivery of Enzymes From Administration of VIOKASE16 in Exocrine Pancreatic Insufficiency (EPI)An Open-Label Cross-over Study to Evaluate the Intraduodenal Delivery of Lipase, Protease and Amylase From Administration of VIOKASE16 in Chronic Pancreatitis Subjects With Exocrine Pancreatic Insufficiency (EPI).Exocrine Pancreatic InsufficiencyDrug: VIOKASE 16Axcan PharmaAAIPharma;Mayo Clinical Services;City Hospital Laboratory BirminghamNot recruiting18 YearsN/ABoth22Phase 2United States;Czech Republic
59NCT00658736March 200816 December 2017Efficacy of EUS-guided Celiac Plexus Blockade in Chronic PancreatitisA Randomized, Triple-Blinded Study of Endoscopic Ultrasound Guided Celiac Plexus Blockade (EUS-CPB) With Bupivicaine and Triamcinolone vs. Bupivicaine Alone for the Treatment of Pain in Chronic PancreatitisChronic PancreatitisDrug: Triamcinolone;Drug: Bupivicaine aloneThe Cleveland ClinicAmerican Society for Gastrointestinal Endoscopy;TAP Pharmaceutical Products Inc.Not recruiting18 YearsN/AAll40Phase 3United States
60EUCTR2007-004004-12-BG28/02/200819 March 2012A STUDY TO INVESTIGATE THE EFFECT OF PANCRELIPASE DELAYED RELEASE CAPSULES ON MALDIGESTION IN PATIENTS WITH EXOCRINE PANCREATIC INSUFFICIENCY DUE TO CHRONIC PANCREATITIS AND PANCREATECTOMYA STUDY TO INVESTIGATE THE EFFECT OF PANCRELIPASE DELAYED RELEASE CAPSULES ON MALDIGESTION IN PATIENTS WITH EXOCRINE PANCREATIC INSUFFICIENCY DUE TO CHRONIC PANCREATITIS AND PANCREATECTOMYPancreatic enzyme replacement therapy is the cornerstone of nutritional management of pancreatic exocrine insufficiency (PEI) due to e.g. cystic fibrosis, chronic pancreatitis, partial or complete pancreatectomy or gastrectomy. Without pancreatic enzyme replacement the patients suffer from severe symptoms of maldigestion as manifested by steatorrhea, abdominal pain, body weight loss etc.
MedDRA version: 9.1 Level: LLT Classification code 10009093 Term: Chronic pancreatitis
MedDRA version: 9.1 Level: LLT Classification code 10033596 Term: Pancreatectomy
Trade Name: Creon 10000
Product Name: Pancrelipase Delayed Release Capsule
Pharmaceutical Form: Capsule, hard
Other descriptive name: Pancrelipase/Pancreas Powder
Concentration unit: IU international unit(s)
Concentration type: equal
Concentration number: 12000-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Trade Name: Creon 25000
Product Name: Pancrelipase Delayed Release Capsule
Pharmaceutical Form: Capsule, hard
Other descriptive name: Pancrelipase/Pancreas Powder
Concentration unit: IU international unit(s)
Concentration type: equal
Concentration number: 24000-
Solvay Pharmaceuticals GmbHNot RecruitingFemale: yes
Male: yes
52Bulgaria
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
61EUCTR2007-000375-42-DK21/02/200819 March 2012A multi-center, double-blind, parallel-design, randomized, placebo-controlled, dose-ranging study to assess the efficacy and safety of oral recombinant microbial lipase (SLV339) in subjects with pancreatic exocrine insufficiency due to chronic pancreatitisA multi-center, double-blind, parallel-design, randomized, placebo-controlled, dose-ranging study to assess the efficacy and safety of oral recombinant microbial lipase (SLV339) in subjects with pancreatic exocrine insufficiency due to chronic pancreatitisPancreatic exocrine insufficiency due to chronic pancreatitis
MedDRA version: 9.1 Level: LLT Classification code 10009093 Term: Chronic pancreatitis
Product Name: Recombinant microbial lipase
Product Code: SLV339
Pharmaceutical Form: Capsule, hard
Current Sponsor code: SLV339
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Solvay Pharmaceuticals GmbHNot RecruitingFemale: yes
Male: yes
80Hungary;Czech Republic;Denmark;Latvia;Sweden
62NCT00620919February 200819 February 2015Secretin Enhanced Multidetector CT Pancreatography for Evaluation of Known or Suspected Chronic PancreatitisRG1068 (Synthetic Human Secretin) Enhanced Multidetector CT Pancreatography: Evaluation of the Pancreatic Duct in Patients With Known or Suspected Chronic PancreatitisChronic PancreatitisDrug: RG1068 (Synthetic Human Secretin)Massachusetts General HospitalNot recruiting18 Years90 YearsBoth0Phase 1United States
63NCT00621283February 200819 February 2015Secretin Enhanced MRCP for Evaluation of Pancreatic Duct in Pediatric PopulationRG1068 (Synthetic Human Secretin) Enhanced MRCP for Morphological Evaluation of the Pancreatic Duct in the Pediatric PopulationAcute Recurrent Pancreatitis;Chronic PancreatitisDrug: RG1068 (Synthetic Human Secretin)Massachusetts General HospitalNot recruiting2 Years18 YearsBoth0Phase 1United States
64NCT00788593January 200819 October 2017A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 (APT-1008) in Chronic Pancreatitis (CP) Participants With Exocrine Pancreatic Insufficiency (EPI)A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 in Chronic Pancreatitis (CP) Patients With Exocrine Pancreatic Insufficiency (EPI)Chronic Pancreatitis;Exocrine Pancreatic InsufficiencyDrug: Placebo;Drug: EUR-1008 (APT-1008) High Dose;Drug: EUR-1008 (APT-1008) Low DoseForest LaboratoriesNot recruiting18 YearsN/AAll82Phase 3United States;Italy;Ukraine
65NCT00500084December 200719 February 2015Phase III ALTU-135 CP Safety TrialAn Open-Label Clinical Study Evaluating the Long Term Safety of ALTU-135 in the Treatment of Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis or PancreatectomyExocrine Pancreatic InsufficiencyDrug: LiprotamaseAnthera PharmaceuticalsNot recruiting18 YearsN/ABoth39Phase 3United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
66NCT00559364November 200716 December 2017Safety and Efficacy Study of Viokase® 16 for the Correction of SteatorrheaA Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled, Phase III Study to Assess the Safety and Efficacy of Viokase® 16 for the Correction of Steatorrhea in Patients With Exocrine Pancreatic InsufficiencyExocrine Pancreatic Insufficiency;Chronic Pancreatitis;PancreatectomyDrug: Viokase® 16;Drug: Placebo;Drug: Proton pump inhibitor (PPI);Drug: OmeprazoleForest LaboratoriesNot recruiting18 Years80 YearsAll50Phase 3United States;Canada;Poland;Slovakia;Germany
67NCT00414908October 200719 October 2017A Study to Investigate the Effect of Delayed Release Pancrelipase on Maldigestion in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis and PancreatectomyA Study to Investigate the Effect of Delayed Release Pancrelipase on Maldigestion in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis and PancreatectomyChronic Pancreatitis;Pancreatectomy;Pancreatic Exocrine InsufficiencyDrug: Pancrelipase delayed release capsule;Drug: Placebo ComparatorSolvay PharmaceuticalsNot recruiting18 YearsN/AAll52Phase 3United States;Bulgaria;Poland;Puerto Rico;Russian Federation;Serbia;South Africa;Ukraine;Former Serbia and Montenegro
68EUCTR2006-006958-10-GB26/09/200719 March 2012Anticipate Trial - Randomized, Double blind, placebo-controlled, multicentre Trial of Anti-oxidant therapy in painful chronic pancreatitis. - Aniticipate trialAnticipate Trial - Randomized, Double blind, placebo-controlled, multicentre Trial of Anti-oxidant therapy in painful chronic pancreatitis. - Aniticipate trialChronic PancreatitisProduct Name: Antox version 1.2
Pharmaceutical Form: Coated tablet
Pharmaceutical form of the placebo: Coated tablet
Route of administration of the placebo: Oral use
Pharmanord, UK, LTDAuthorisedFemale: yes
Male: yes
60United Kingdom
69NCT00400842May 200719 February 2015A Study of SA-001 to Treat Pancreatic Exocrine InsufficiencyA Double-blind, Placebo-controlled, Parallel-group, Comparative Study to Confirm the Safety and Efficacy of Oral 1.5 g/Day and 3.0 g/Day of SA-001 in Patients With Pancreatic Exocrine Insufficiency Caused by Chronic Pancreatitis or by PancreatectomyExocrine Pancreatic Insufficiency, Chronic PancreatitisDrug: SA-001;Drug: PlaceboAbbottNot recruiting20 YearsN/ABoth274Phase 3Japan
70NCT00588367April 200628 April 2015CT Pancreas PerfusionCT Perfusion of Pancreatic Cancer and Chronic Pancreatitis: Feasibility StudyPancreatic Ductal Adenocarcinoma;Chronic Pancreatitis;Autoimmune PancreatitisDevice: Mayo Interactive Breath Hold MonitorMayo ClinicNot recruiting18 YearsN/ABoth30N/AUnited States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
71NCT00156403August 200519 February 2015A Pilot Study of Use of Calcium Channel Blocker to Decrease Inflammation and Pain in Hereditary PancreatitisHereditary Pancreatitis Amlodipine Trial(H-PAT): A Pilot StudyPancreatitisDrug: amlodipine (drug)University of PittsburghNational Center for Research Resources (NCRR)Not recruiting6 YearsN/ABoth8Phase 1/Phase 2United States
72NCT00469703August 200519 February 2015Safety and Efficacy Study of Thalomid in Patients With Chronic PancreatitisA Phase II, Open-Label, Single Center Pilot Study to Determine the Safety and Efficacy of THALOMID (Thalidomide) in Patients With Chronic Pancreatitis.Chronic PancreatitisDrug: ThalidomideWinthrop University HospitalCelgene CorporationNot recruiting18 Years75 YearsBoth10Phase 2United States
73EUCTR2005-000736-24-DE14/07/200510 February 2014RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED PHASE IV TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF AN ENTERIC-COATED PANCREATIN TABLET FOR LIPID DIGESTION AND ABSORPTION IN PATIENTS WITH PANCREATIC EXOCRINE INSUFFICIENCY DUE TO CHRONIC PANCREATITIS BY MEANS OF 13C-MIXED TRIGLYCERIDE BREATH TEST - CPI 003RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED PHASE IV TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF AN ENTERIC-COATED PANCREATIN TABLET FOR LIPID DIGESTION AND ABSORPTION IN PATIENTS WITH PANCREATIC EXOCRINE INSUFFICIENCY DUE TO CHRONIC PANCREATITIS BY MEANS OF 13C-MIXED TRIGLYCERIDE BREATH TEST - CPI 003The purpose of this trial is to evaluate the clinical efficacy and safety of an enteric-coated pancreatin tablet in comparison to placebo in the treatment of pancreatic exocrine insufficiency due to chronic pancreatitis.
MedDRA version: 7.0 Level: LLT Classification code 10033628
Trade Name: Helopanflat Mono®
Product Name: Helopanflat Mono®
Product Code: Pancreatin
Pharmaceutical Form: Gastro-resistant tablet
INN or Proposed INN: Pancreatin
Concentration unit: IU international unit(s)
Concentration type: not less then
Concentration number: 10000 IU-lipase
Pharmaceutical form of the placebo: Gastro-resistant tablet
Route of administration of the placebo: Oral use
Berlin-Chemie AGNot RecruitingFemale: yes
Male: yes
20Phase 4Germany
74NCT00142233June 6, 200526 November 2018EUROPAC-2 - Pain Treatment of Hereditary and Idiopathic PancreatitisDouble Blind Randomised Controlled Trial to Investigate the Efficacy of ANTOX (Vers) 1.2 and MGCT (Magnesiocard) for the Treatment of Hereditary Pancreatitis and Idiopathic Chronic PancreatitisPancreatitisDietary Supplement: ANTOX (vers.)1.2;Drug: Magnesium;Other: Placebo ANTOX (vers)1.2;Other: Placebo Magnesiocard (2.5 mmol)University Medicine GreifswaldNot recruiting5 Years75 YearsAll295Phase 3Germany
75NCT01154608April 200519 February 2015Effect of Enzyme Therapy on Protein Metabolism in Chronic PancreatitisPancreatitisDrug: Creon;Other: No enzyme therapyInstitut National de la Recherche AgronomiqueNational Research Agency, France;Solvay PharmaceuticalsNot recruiting18 YearsN/ABoth11N/AFrance
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
76EUCTR2004-002468-89-DE28/10/200419 March 2012A RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED PHASE IV TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PANCREATIN VS. PLACEBO FOR LIPID DIGESTION AND ABSORPTION IN PATIENTS WITH PANCREATIC EXOCRINE INSUFFICIENCY - Pancreatin vs. Placebo in Patients with Pancreatic Exocrine InsufficiencyA RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED PHASE IV TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PANCREATIN VS. PLACEBO FOR LIPID DIGESTION AND ABSORPTION IN PATIENTS WITH PANCREATIC EXOCRINE INSUFFICIENCY - Pancreatin vs. Placebo in Patients with Pancreatic Exocrine InsufficiencyThe purpose of this clinical trial is to evaluate the clinical efficacy and safety of a capsule containing enteric-coated porcine pancreatin microfilm tablets in comparison with placebo in the treatment of pancreatic exocrine insufficiency due to chronic pancreatitis.
MedDRA version: 7.0 Level: LLT Classification code 10033622
Trade Name: Panzytrat 25.000
Product Name: Panzytrat 25.000
Product Code: Pancreatin
Pharmaceutical Form: Capsule*
INN or Proposed INN: Pancreatin
Concentration unit: IU international unit(s)
Concentration type: equal
Concentration number: 25.000-IU lipase
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use
Axcan Pharma S.A.Not RecruitingFemale: yes
Male: yes
20Phase 4Germany
77NCT00957151April 200419 February 2015Evaluation of the Digestive and Metabolic Utilisation of Dietary Protein in Patients With Chronic PancreatitisEvaluation of the Digestive and Metabolic Utilisation of Dietary Protein in Patients With Chronic PancreatitisChronic PancreatitisDrug: CreonHospital AvicenneSolvay PharmaceuticalsNot recruiting18 Years65 YearsBoth12Phase 4France
78NCT00319358October 200319 February 2015Role of Antioxidants Supplementation in Chronic PancreatitisEffect of Antioxidant Supplementation on Pain, Antioxidant Profile and Oxidative Stress in Patients With Chronic PancreatitisChronic PancreatitisDietary Supplement: Antioxidants;Dietary Supplement: PlaceboAll India Institute of Medical Sciences, New DelhiNot recruiting12 Years70 YearsBoth127Phase 3India
79NCT00583271June 200219 February 2015A Prospective Study of EUS Guided Celiac BlockA Prospective Study of Endoscopic Ultrasound-guided Celiac (CB) EffectivenessChronic Pancreatitis;Pancreatic CancerDrug: triamcinolone;Drug: 98% dehydrated alcoholIndiana UniversityNot recruiting18 YearsN/ABoth127N/AUnited States

先頭へ